{"filing": {"accession": "0001493152-26-047586", "cik": "0001763950", "ticker": "LTRN", "company_name": "Lantern Pharma Inc.", "form_type": "DEF 14A", "filing_type": "DEF 14A", "filing_date": "2026-10-19", "accepted_datetime": null, "acceptance_datetime": null, "accepted_at": null, "primary_doc_url": "https://www.sec.gov/Archives/edgar/data/1763950/000149315226047586/0001493152-26-047586-index.htm", "filing_url": "https://www.sec.gov/Archives/edgar/data/1763950/000149315226047586/0001493152-26-047586-index.htm", "period_of_report": "2026-10-19"}, "html_url": "/api/filings/000149315226047586/stream", "exhibits": [], "sections": [], "tables": [{"table_index": 0, "table_type": "text", "caption": null, "header_text": "Filed\n by Registrant\u2612"}, {"table_index": 1, "table_type": "text", "caption": null, "header_text": "\u2610Preliminary\n Proxy Statement"}, {"table_index": 2, "table_type": "exhibit_index", "caption": null, "header_text": "\u2612No\n fee required."}, {"table_index": 4, "table_type": "text", "caption": null, "header_text": "Sincerely,"}, {"table_index": 6, "table_type": "text", "caption": null, "header_text": "1.To\n elect six (6) directors to serve as members of the Board of Directors of the Company (which we refer to as our \u201cBoard\u201d)\n until the next annual meeting of stockholders and until their successors "}, {"table_index": 7, "table_type": "text", "caption": null, "header_text": "/s/\n Donald J. Keyser"}, {"table_index": 9, "table_type": "text", "caption": null, "header_text": "Page"}, {"table_index": 13, "table_type": "text", "caption": null, "header_text": "\u25cfTo\n vote in person, attend the Annual Meeting and follow the procedures set forth in \u201cVoting at the Meeting\u201d, below."}, {"table_index": 14, "table_type": "text", "caption": null, "header_text": "\u25cfFOReach of the six (6) nominees for director named in the Proxy Statement;"}, {"table_index": 17, "table_type": "text", "caption": null, "header_text": "\u25cfdelivering\n to our corporate secretary a signed written notice of revocation, bearing a date later than the date of the proxy, stating that the\n proxy is revoked;"}, {"table_index": 24, "table_type": "text", "caption": null, "header_text": "NameAgePosition"}, {"table_index": 25, "table_type": "text", "caption": null, "header_text": "(a)Member\n of the Audit Committee of our Board."}, {"table_index": 32, "table_type": "text", "caption": null, "header_text": "\u25cfselects\n a qualified firm to serve as the independent registered public accounting firm to audit our financial statements;"}, {"table_index": 35, "table_type": "text", "caption": null, "header_text": "\u25cfreviews,\n approves and determines the compensation of our executive officers;"}, {"table_index": 36, "table_type": "text", "caption": null, "header_text": "\u25cfidentifies,\n evaluates and makes recommendations to our Board regarding nominees for election to our Board and its committees;"}, {"table_index": 45, "table_type": "text", "caption": null, "header_text": "\u25cfalign\n the interests of our stockholders and recipients of awards under the Equity Incentive Plan by increasing the proprietary interests\n of such recipients in the Company\u2019s growth and success;"}, {"table_index": 46, "table_type": "financial", "caption": null, "header_text": "\u25cfnon-qualified\n stock options;"}, {"table_index": 49, "table_type": "text", "caption": null, "header_text": "\u25cfThe\n Equity Incentive Plan is administered by our Board, unless the Board appoints a committee with the authority to administer the Plan.\n Our Compensation Committee, comprised entirely of independen"}, {"table_index": 60, "table_type": "text", "caption": null, "header_text": "Plan categoryNumber of securities\n to be issued upon exercise of outstanding options, warrants and rightsWeighted-average exercise\n price of outstanding options, warrants and rightsNumber of securitie"}, {"table_index": 67, "table_type": "text", "caption": null, "header_text": "20252024"}, {"table_index": 68, "table_type": "text", "caption": null, "header_text": "(A)The audit fees consisted of fees for the audit of our financial statements, the review of the interim financial statements included\n in our quarterly reports on Form 10-Q, and other professional se"}, {"table_index": 71, "table_type": "text", "caption": null, "header_text": "\u25cfThe\n Audit Committee has reviewed and discussed the audited consolidated financial statements for the year ended December 31, 2025 with\n management of Lantern Pharma Inc. and with Lantern Pharma Inc."}, {"table_index": 79, "table_type": "text", "caption": null, "header_text": "Shares\n Beneficially Owned"}, {"table_index": 80, "table_type": "text", "caption": null, "header_text": "*Represents\n less than 1% of shares outstanding."}, {"table_index": 83, "table_type": "text", "caption": null, "header_text": "(4)Consists\n of 109,178 shares of common stock subject to options exercisable within 60 days. Excludes 5,422 shares of common stock underlying\n options which are subject to vesting conditions."}, {"table_index": 86, "table_type": "text", "caption": null, "header_text": "NameAgePosition"}, {"table_index": 87, "table_type": "text", "caption": null, "header_text": "Name\n and Principal PositionYearSalary($)Bonus($)Option\n Awards($)(1)(2)Other\n Compensation($)(3)Total($)"}, {"table_index": 88, "table_type": "text", "caption": null, "header_text": "(1)For\n 2025, the fair value of the options granted was estimated using the Black-Scholes option-pricing model using the following weighted\n average assumptions: term of 5.52 years, risk free rate of "}, {"table_index": 95, "table_type": "text", "caption": null, "header_text": "Option\n Awards"}, {"table_index": 96, "table_type": "text", "caption": null, "header_text": "(1)The\n options vest and first become exercisable in equal monthly increments over a 24-month period commencing on the one-month anniversary\n of the date of grant."}, {"table_index": 99, "table_type": "text", "caption": null, "header_text": "YearSummary\n Compensation Table Total for CEO(1)Compensation\n Actually Paid to CEO(2)Average Summary CompensationTable\n Total for Non-CEO NEOs(3)Average\n Compensation Actually Paid to Non-CEO NEOs(4)V"}, {"table_index": 100, "table_type": "text", "caption": null, "header_text": "(1)The\n dollar amounts reported are the amounts of total compensation reported for our CEO, Panna Sharma, in the Summary Compensation Table\n for fiscal years 2025 and 2024."}, {"table_index": 102, "table_type": "text", "caption": null, "header_text": "(2)The\n dollar amounts reported are the amounts of total compensation reported for Mr. Sharma in the Summary Compensation Table for the applicable\n year, excluding the reported value for equity awards"}, {"table_index": 103, "table_type": "text", "caption": null, "header_text": "YearSummary\n Compensation Table Total for CEOReported\n Value of Equity Awards for CEO(1)Fair\n Value as of Year End for Unvested Awards Granted During the YearFair\n Value Year over Year Increase or Dec"}, {"table_index": 107, "table_type": "text", "caption": null, "header_text": "YearSummary\n CompensationTable\n Total for Non-CEO NEOsReported\n Value of Equity Awards for Non-CEO NEOs(1)Fair\n Value as of Year End for Unvested Awards Granted During the YearFair\n Value Year over Ye"}, {"table_index": 109, "table_type": "text", "caption": null, "header_text": "NameFees\n Earned or Paid in Cash($)Option\n Awards (2)($)Total($)"}, {"table_index": 110, "table_type": "text", "caption": null, "header_text": "(1)Dr.\n Schalop joined the Board in July 2025."}, {"table_index": 113, "table_type": "financial", "caption": null, "header_text": "\u25cfthe\n amounts involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our total assets at year-end for the last\n two completed fiscal years; and"}, {"table_index": 116, "table_type": "text", "caption": null, "header_text": "By\n Order of the Board of Directors"}, {"table_index": 118, "table_type": "text", "caption": null, "header_text": "By:"}], "exhibits_pending": false, "cdn_html": true, "response_time_ms": 47}